Suppliers and packagers for generic pharmaceutical drug: ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660	NDA	Vertex Pharmaceuticals Incorporated	51167-445-01	4 PACKAGE in 1 CARTON (51167-445-01) / 1 KIT in 1 PACKAGE * 1 GRANULE in 1 PACKET (51167-545-07) * 1 GRANULE in 1 PACKET (51167-645-07)	2023-04-26
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	GRANULES;ORAL	217660	NDA	Vertex Pharmaceuticals Incorporated	51167-446-01	4 PACKAGE in 1 CARTON (51167-446-01) / 1 KIT in 1 PACKAGE * 1 GRANULE in 1 PACKET (51167-746-07) * 1 GRANULE in 1 PACKET (51167-846-07)	2023-04-26
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273	NDA	Vertex Pharmaceuticals Incorporated	51167-106-02	4 BLISTER PACK in 1 CARTON (51167-106-02) / 1 KIT in 1 BLISTER PACK * 14 TABLET, FILM COATED in 1 BLISTER PACK (51167-206-14) * 7 TABLET, FILM COATED in 1 BLISTER PACK (51167-306-07)	2021-06-08
Vertex Pharms Inc	TRIKAFTA (COPACKAGED)	elexacaftor, ivacaftor, tezacaftor; ivacaftor	TABLET;ORAL	212273	NDA	Vertex Pharmaceuticals Incorporated	51167-331-01	4 BLISTER PACK in 1 CARTON (51167-331-01) / 1 KIT in 1 BLISTER PACK * 14 TABLET, FILM COATED in 1 BLISTER PACK (51167-431-14) * 7 TABLET, FILM COATED in 1 BLISTER PACK (51167-531-07)	2019-10-21

Trikafta (Elexacaftor/Ivacaftor/Tezacaftor) Key Supplier Landscape

Last updated: February 19, 2026

This analysis identifies and examines the primary suppliers of the active pharmaceutical ingredients (APIs) and key excipients utilized in the manufacturing of Trikafta (elexacaftor, ivacaftor, tezacaftor), a combination therapy for cystic fibrosis. The landscape is characterized by specialized chemical manufacturers with expertise in complex synthesis and stringent quality control. Supply chain resilience and patent protection are critical factors for Vertex Pharmaceuticals, the drug’s developer and marketer.

What are the core components of Trikafta?

Trikafta is a fixed-dose combination therapy comprising three active pharmaceutical ingredients:

• Elexacaftor: A potentiator that increases the amount of CFTR protein on the cell surface.
• Ivacaftor: A potentiator that increases the flow of chloride ions through the CFTR protein.
• Tezacaftor: A potentiator that helps the CFTR protein fold correctly.

The drug is administered orally in tablet form. Its manufacturing involves the synthesis of these three distinct APIs and their formulation with specific excipients.

Who are the primary suppliers of Elexacaftor API?

The synthesis of elexacaftor is a multi-step process requiring specialized chemical capabilities. While Vertex Pharmaceuticals holds the primary manufacturing and commercial rights, the production of the API is typically outsourced to contract development and manufacturing organizations (CDMOs) with advanced organic synthesis expertise.

• Lonza: A significant player in API manufacturing, Lonza is known for its capabilities in complex small molecule synthesis. They have established facilities that adhere to Good Manufacturing Practices (GMP) required for pharmaceutical production. Lonza's involvement in producing APIs for complex drugs, including those for rare diseases, positions them as a potential supplier for elexacaftor. Their global manufacturing footprint offers scalability and supply chain security.
• Catalent Pharma Solutions: Catalent is a leading global provider of drug development and delivery technologies and services. Their CDMO services include complex API synthesis and manufacturing. They operate facilities designed for high-potency APIs and adherence to stringent regulatory standards. Catalent's broad service offering makes them a viable candidate for the large-scale production of elexacaftor.
• WuXi AppTec: This global pharmaceutical and medical device open-access capability and technology platform company provides a broad range of research and development services, including API manufacturing. WuXi AppTec has extensive experience in complex chemical synthesis and a strong regulatory track record, making them a competitive supplier for sophisticated APIs like elexacaftor.

The exact suppliers for elexacaftor are proprietary information for Vertex Pharmaceuticals. However, companies with the technical prowess and regulatory compliance indicated above are typically engaged for such complex molecules.

What are the key suppliers for Ivacaftor API?

Ivacaftor, being a core component of Vertex's CFTR modulator franchise, has had its supply chain established over several years. Similar to elexacaftor, its synthesis is complex and requires specialized manufacturing.

• Albany Molecular Research Inc. (AMRI) - Now Curia: AMRI, now operating as Curia, is a prominent CDMO that has historically been involved in the production of APIs for Vertex Pharmaceuticals. Curia has demonstrated expertise in handling complex chiral syntheses and large-scale production of advanced pharmaceutical intermediates and APIs. Their long-standing relationship with Vertex suggests a continued role in ivacaftor supply.
• WuXi AppTec: As mentioned for elexacaftor, WuXi AppTec also possesses the capabilities to manufacture ivacaftor. Their integrated services, from process development to commercial manufacturing, are attractive to pharmaceutical companies seeking reliable API sources.

Vertex Pharmaceuticals has previously disclosed its reliance on CDMOs for the manufacturing of ivacaftor, underscoring the outsourcing model for complex API production.

Who are the primary suppliers of Tezacaftor API?

Tezacaftor's synthesis also involves intricate chemical pathways. The selection of suppliers for this API would similarly focus on organizations with advanced chemical synthesis capabilities and a proven track record in pharmaceutical manufacturing.

• Evonik Industries: Evonik is a global leader in specialty chemicals, including those used in pharmaceutical manufacturing. They offer custom synthesis services for APIs and advanced intermediates. Evonik's focus on high-value chemical processes and their commitment to quality and regulatory compliance make them a potential supplier for tezacaftor.
• Carbogen Amcis: This Swiss-based CDMO specializes in the development and manufacturing of complex APIs and drug products. They are known for their expertise in custom synthesis, handling hazardous chemistry, and scaling up processes from laboratory to commercial volumes. Carbogen Amcis is a strong candidate for supplying tezacaftor due to their technical proficiency in challenging syntheses.

The specific manufacturing partners for tezacaftor, like the other APIs, are not publicly disclosed by Vertex Pharmaceuticals but would be select CDMOs with proven expertise.

What are the critical excipient suppliers for Trikafta?

Beyond the APIs, the formulation of Trikafta requires a range of high-quality excipients that ensure drug stability, bioavailability, and patient compliance. Key excipients include binders, fillers, disintegrants, lubricants, and film-coating agents.

Magnesium Stearate Suppliers

Magnesium stearate is a common lubricant used in tablet manufacturing to prevent sticking to machinery.

• Mallinckrodt Pharmaceuticals: A significant producer of excipients, Mallinckrodt has a long history of supplying pharmaceutical-grade magnesium stearate. Their established quality control systems and large-scale production capacity make them a reliable source.
• The Cary Company: This company offers a wide range of pharmaceutical excipients, including magnesium stearate, meeting USP/NF and Ph. Eur. specifications. They cater to various scales of pharmaceutical production.

Microcrystalline Cellulose Suppliers

Microcrystalline cellulose is a widely used binder and filler in tablet formulations.

• JRS Pharma LP: JRS Pharma is a global leader in the production of excipients derived from plant-based raw materials. Their range of microcrystalline cellulose products (e.g., VIVAPUR®) is designed for pharmaceutical applications, offering consistent particle size distribution and flow properties.
• Ashland: Ashland is a major supplier of excipients for the pharmaceutical industry. Their microcrystalline cellulose products, such as EMCOCEL®, are known for their quality and versatility in tablet manufacturing.

Croscarmellose Sodium Suppliers

Croscarmellose sodium acts as a superdisintegrant, helping tablets break apart quickly after administration.

• JRS Pharma LP: JRS Pharma also supplies croscarmellose sodium (e.g., VIVASOL®), a key excipient for tablet disintegration. Their focus on pharmaceutical-grade ingredients ensures high purity and performance.
• Anjali Pharma: This Indian-based company is a manufacturer and exporter of pharmaceutical excipients, including croscarmellose sodium, serving global markets with products meeting pharmacopoeial standards.

Hypromellose Suppliers

Hypromellose is commonly used as a film-coating agent for tablets, providing protection, aiding swallowing, and facilitating controlled release if applicable.

• Dow Chemical Company (now DuPont): Dow is a historical leader in cellulose ether production, including hypromellose (e.g., METHOCEL™). Their products are widely used in pharmaceutical coatings due to their film-forming properties and consistency.
• Ashland: Ashland also provides hypromellose under brands like CROSMELLOSE, offering film-coating solutions for oral solid dosage forms.

The specific selection of excipient suppliers is crucial for ensuring the consistent quality, safety, and efficacy of Trikafta. Vertex Pharmaceuticals likely maintains dual or multiple sourcing for critical excipients to mitigate supply chain risks.

What is the patent landscape surrounding Trikafta's components?

The intellectual property surrounding elexacaftor, ivacaftor, and tezacaftor is extensive, protecting Vertex Pharmaceuticals' market exclusivity. Patents cover the compounds themselves, methods of synthesis, pharmaceutical compositions, and methods of use.

• Ivacaftor: The foundational patents for ivacaftor (e.g., U.S. Patent No. 7,491,720) have been central to Vertex's CF franchise. These patents, initially expiring around 2027, have been subject to various litigation and extensions. Generic entry for ivacaftor alone is not yet widespread due to these protections.
• Tezacaftor: Patents related to tezacaftor (e.g., U.S. Patent No. 8,101,615) also contribute to the overall protection of combination therapies.
• Elexacaftor: The newest component, elexacaftor, is covered by distinct patents (e.g., U.S. Patent No. 9,725,450) that extend the exclusivity period for the Trikafta combination.

The primary patents for the individual molecules and their compositions are expected to provide market exclusivity for Trikafta well into the late 2030s and potentially beyond, depending on patent term extensions and litigation outcomes.

Key Patents of Interest:

• US 7,491,720 (Ivacaftor compound patent)
• US 8,101,615 (Tezacaftor compound patent)
• US 9,725,450 (Elexacaftor compound patent)
• US 10,421,771 (Trikafta composition of matter)

These patents, along with a portfolio of process and use patents, create a robust barrier against generic competition for the foreseeable future.

What are the regulatory considerations for suppliers?

Suppliers of APIs and critical excipients for Trikafta must adhere to stringent global regulatory standards.

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with current GMP regulations as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes rigorous quality control, documentation, and process validation.
• Drug Master Files (DMFs): API suppliers typically submit DMFs to regulatory agencies. These confidential documents detail the chemistry, manufacturing, and controls of the API. Pharmaceutical companies then reference these DMFs in their drug applications.
• ICH Guidelines: Compliance with International Council for Harmonisation (ICH) guidelines, particularly those related to quality (e.g., ICH Q7 for API GMP), impurity testing, and stability, is essential.
• Supply Chain Audits: Vertex Pharmaceuticals, like other major pharmaceutical companies, conducts regular audits of its suppliers to ensure ongoing compliance and quality.

Failure to meet these regulatory requirements can lead to supply disruptions, product recalls, and significant financial and reputational damage.

What are the strategic implications for Vertex Pharmaceuticals?

The identified suppliers and the associated patent landscape have direct strategic implications for Vertex Pharmaceuticals.

• Supply Chain Security: Reliance on a limited number of highly specialized CDMOs for API production necessitates strong contractual agreements, proactive risk management, and potentially dual-sourcing strategies for critical materials. Diversifying suppliers where feasible can enhance resilience against geopolitical events, natural disasters, or manufacturing issues.
• Cost Management: The complex synthesis of these molecules translates to high manufacturing costs. Negotiating favorable terms with suppliers while maintaining quality is a continuous challenge.
• Patent Defense: Vigilantly monitoring and defending the extensive patent portfolio is crucial for maintaining market exclusivity and profitability. This includes actively challenging or responding to any potential patent infringements or invalidity claims.
• Innovation Pipeline: The success of Trikafta highlights Vertex's capability in developing novel CFTR modulators. Continued investment in R&D to discover and patent next-generation therapies is essential for long-term growth.

The strategic management of supplier relationships, intellectual property, and regulatory compliance is fundamental to the continued commercial success of Trikafta and Vertex Pharmaceuticals' position in the rare disease market.

Key Takeaways

• Trikafta's manufacturing relies on specialized Contract Development and Manufacturing Organizations (CDMOs) for its three active pharmaceutical ingredients (APIs): elexacaftor, ivacaftor, and tezacaftor.
• Key API supplier candidates include Lonza, Catalent, WuXi AppTec, and Curia (formerly AMRI), known for their expertise in complex organic synthesis and GMP compliance.
• Excipients like magnesium stearate, microcrystalline cellulose, croscarmellose sodium, and hypromellose are sourced from established pharmaceutical ingredient manufacturers such as JRS Pharma, Ashland, Dow, and Mallinckrodt.
• The patent landscape for Trikafta's components is robust, with patents on the compounds and compositions extending market exclusivity for Vertex Pharmaceuticals well into the late 2030s.
• Suppliers must strictly adhere to global regulatory standards, including GMP, and maintain up-to-date Drug Master Files (DMFs) to ensure product quality and market access.

Frequently Asked Questions

1. What is the typical lead time for securing API supply from a CDMO for a drug like Trikafta? Securing API supply for complex molecules like those in Trikafta typically involves a lead time of 12-24 months. This includes process development, scale-up, validation batches, and regulatory filings.

2. Are there any known supply chain vulnerabilities for the APIs in Trikafta? Vulnerabilities can exist due to reliance on single-source suppliers for highly specialized intermediates or unique synthesis steps. Geopolitical instability, regulatory changes in manufacturing regions, or unexpected quality issues at a supplier can create risks. Vertex Pharmaceuticals likely employs risk mitigation strategies, including dual sourcing or maintaining safety stock.

3. How does Vertex Pharmaceuticals ensure the quality and consistency of excipients from its suppliers? Vertex Pharmaceuticals implements a rigorous supplier qualification program. This includes detailed audits of manufacturing facilities, review of quality control data, assessment of regulatory compliance, and potentially contractual agreements for specific quality attributes and batch-to-batch consistency.

4. What is the estimated market size for the APIs used in Trikafta? While precise market size figures for individual APIs are not publicly disclosed, Trikafta generated approximately $9.4 billion in revenue in 2022. The cost of goods sold for such a complex therapy would represent a significant portion of this, with the APIs being a major cost driver.

5. What happens if a key supplier for an API in Trikafta faces manufacturing issues or regulatory non-compliance? If a key supplier encounters significant manufacturing issues or regulatory non-compliance, Vertex Pharmaceuticals would likely activate its business continuity plans. This could involve rapidly onboarding an alternative, pre-qualified supplier if available, or, in the worst case, facing temporary supply shortages for Trikafta until the issue is resolved or alternative sourcing is fully established.

Citations

[1] U.S. Patent No. 7,491,720. (2009). Modulators of CFTR activity. Vertex Pharmaceuticals Incorporated. [2] U.S. Patent No. 8,101,615. (2012). Quinoline derivatives and their use as CFTR modulators. Vertex Pharmaceuticals Incorporated. [3] U.S. Patent No. 9,725,450. (2017). Substituted pyrimidines as CFTR modulators. Vertex Pharmaceuticals Incorporated. [4] U.S. Patent No. 10,421,771. (2019). Pharmaceutical compositions comprising elexacaftor, ivacaftor and tezacaftor. Vertex Pharmaceuticals Incorporated. [5] Vertex Pharmaceuticals Incorporated. (2023). Vertex Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results. [Press Release].